## Stefania Landolfi

## List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/2902450/stefania-landolfi-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

66 3,287 24 57 h-index g-index citations papers 6.2 69 4.25 3,994 L-index avg, IF ext. citations ext. papers

#	Paper	IF	Citations
66	miRNA landscape in primary tumors and matched metastases in gastrointestinal stromal tumors. <i>Epigenomics</i> , <b>2021</b> , 13, 369-377	4.4	O
65	Young-onset colorectal cancer: A call for action Journal of Clinical Oncology, 2021, 39, 10563-10563	2.2	
64	Acquired hepatocerebral degeneration in a metastatic neuroendocrine tumor long-term survivor - an update on neuroendocrine neoplasm's treatment: A case report. <i>World Journal of Hepatology</i> , <b>2021</b> , 13, 611-619	3.4	
63	Quantifying intraepithelial lymphocytes and subepithelial collagen band in microscopic colitis, extracting insights into the interrelationship of lymphocytic and collagenous colitis. <i>Annals of Diagnostic Pathology</i> , <b>2021</b> , 52, 151741	2.2	O
62	European guidelines on microscopic colitis: United European Gastroenterology and European Microscopic Colitis Group statements and recommendations. <i>United European Gastroenterology Journal</i> , <b>2021</b> , 9, 13	5.3	38
61	Treatment outcomes of advanced digestive well-differentiated grade 3 NETs. <i>Endocrine-Related Cancer</i> , <b>2021</b> , 28, 549-561	5.7	0
60	Methodological approach to Microscopic Colitis diagnosis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2020</b> , 476, 621-622	5.1	
59	Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors. <i>BMC Cancer</i> , <b>2020</b> , 20, 99	4.8	21
58	Epigenetic Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 902-909	12.9	13
57	Mucosal microbial load in Crohn's disease: A potential predictor of response to faecal microbiota transplantation. <i>EBioMedicine</i> , <b>2020</b> , 51, 102611	8.8	12
56	Topographical distribution of microscopic colitis and the importance of orientation of paraffin-embedded biopsies. <i>Human Pathology</i> , <b>2020</b> , 103, 63-71	3.7	7
55	Targeted multiplex proteomics for molecular prescreening and biomarker discovery in metastatic colorectal cancer. <i>Scientific Reports</i> , <b>2019</b> , 9, 13568	4.9	11
54	Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline Imatinib. <i>Oncologist</i> , <b>2019</b> , 24, 680-687	5.7	3
53	TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence. <i>Journal of Clinical Investigation</i> , <b>2018</b> , 128, 3887-3905	15.9	41
52	Translating molecular subtypes of gastric and gastroesophageal junction cancer (GC and GEJC) to the metastatic (met) setting: Prevalence and outcome dataTranslating molecular subtypes of gastric and gastroesophageal junction cancer (GC and GEJC) to the metastatic (met) setting:	2.2	
51	Brief Report: Effectiveness of Trichloroacetic Acid vs. Electrocautery Ablation for the Treatment of Anal High-Grade Squamous Intraepithelial Lesion in HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2018</b> , 79, 612-616	3.1	3
50	Investigation of the role of tyrosine kinase receptor EPHA3 in colorectal cancer. <i>Scientific Reports</i> , <b>2017</b> , 7, 41576	4.9	7

49	Loss of the EPH receptor B6 contributes to colorectal cancer metastasis. Scientific Reports, 2017, 7, 437	<b>02</b> 9	18
48	Risk factors of high-grade anal intraepithelial neoplasia recurrence in HIV-infected MSM. <i>Aids</i> , <b>2017</b> , 31, 1245-1252	3.5	11
47	Analysis of mutant allele fractions in driver genes in colorectal cancer - biological and clinical insights. <i>Molecular Oncology</i> , <b>2017</b> , 11, 1263-1272	7.9	20
46	The role of oncogenic human papillomavirus determination for diagnosis of high-grade anal intraepithelial neoplasia in HIV-infected MSM. <i>Aids</i> , <b>2017</b> , 31, 2227-2233	3.5	21
45	Analysis of persistence and antibiotic response in colorectal cancer. <i>Science</i> , <b>2017</b> , 358, 1443-1448	33.3	578
44	Tankyrase Inhibition Blocks Wnt/ECatenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 644-56	12.9	114
43	Gastrointestinal endarteropathy in adult dermatomyositis. Joint Bone Spine, 2016, 83, 353-4	2.9	2
42	Epigenetic Homogeneity Within Colorectal Tumors Predicts Shorter Relapse-Free and Overall Survival Times for Patients With Locoregional Cancer. <i>Gastroenterology</i> , <b>2016</b> , 151, 961-972	13.3	30
41	The effectiveness of electrocautery ablation for the treatment of high-grade anal intraepithelial neoplasia in HIV-infected men who have sex with men. <i>HIV Medicine</i> , <b>2016</b> , 17, 524-31	2.7	23
40	DPYD Genotyping to Predict Adverse Events Following Treatment With Fluorouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer: A Secondary Analysis of the PETACC-8 Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2016</b> , 2, 655-662	13.4	37
39	Prognostic impact of primary tumor site location in metastatic colorectal cancer (mCRC) <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 578-578	2.2	1
38	Survival determinants with matched targeted therapies in BRAF mutant metastatic colorectal cancer (mCRC) <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 649-649	2.2	1
37	Towards a new paradigm of microscopic colitis: Incomplete and variant forms. <i>World Journal of Gastroenterology</i> , <b>2016</b> , 22, 8459-8471	5.6	18
36	Clonality patterns of driver mutations (mut) to reveal spatial-temporal genomic heterogeneity in colorectal cancer (CRC) <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3509-3509	2.2	
35	Risk of progression to high-grade anal intraepithelial neoplasia in HIV-infected MSM. <i>Aids</i> , <b>2015</b> , 29, 695	5-3.92	29
34	Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4176-87	2.2	347
33	Detailed characterization of MLH1 p.D41H and p.N710D variants coexisting in a Lynch syndrome family with conserved MLH1 expression tumors. <i>Clinical Genetics</i> , <b>2015</b> , 87, 543-8	4	4
32	Myo5b knockout mice as a model of microvillus inclusion disease. <i>Scientific Reports</i> , <b>2015</b> , 5, 12312	4.9	40

31	Cyclin E amplification/overexpression is associated with poor prognosis in gastric cancer. <i>Annals of Oncology</i> , <b>2015</b> , 26, 438-9	10.3	15
30	Actualizacifi de la recomendacifi para la determinacifi de biomarcadores en el carcinoma colorrectal. Consenso Nacional de la Sociedad Espafila de Anatomfi Patolfjica y de la Sociedad Espafila de Oncologfi Mflica. <i>Revista Espanola De Patologia</i> , <b>2015</b> , 48, 14-24	1.2	1
29	Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. <i>Clinical and Translational Oncology</i> , <b>2015</b> , 17, 264-73	3.6	7
28	Outcome evolution of matched molecular targeted agents (MTAs) in metastatic colorectal cancer (CRC) patients (pts): VHIO experience <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3602-3602	2.2	1
27	Clinical and molecular characterization of refractory BRAF mutant metastatic colorectal carcinoma (mCRC): Vall dHebron Institute of Oncology phase I program cohort <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 587-587	2.2	
26	DYPD genotyping to predict toxicity in patients with stage III colon cancer treated with 5-fluorouracil-based adjuvant chemotherapy in the PETACC-8 phase III trial <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3584-3584	2.2	
25	Knocking on molecular alterations in advanced gastric cancer (AGC) <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4063-4063	2.2	
24	SPROUTY2 is a Leatenin and FOXO3a target gene indicative of poor prognosis in colon cancer. <i>Oncogene</i> , <b>2014</b> , 33, 1975-85	9.2	21
23	RHOA inactivation enhances Wnt signalling and promotes colorectal cancer. <i>Nature Communications</i> , <b>2014</b> , 5, 5458	17.4	85
22	Breast-conservative surgery followed by radiofrequency ablation of margins decreases the need for a second surgical procedure for close or positive margins. <i>Clinical Breast Cancer</i> , <b>2014</b> , 14, 346-51	3	9
21	Coexisting KRAS and PIK3CA exon 20 mutations as a potential poor-prognosis factor in metastatic colorectal cancer (mCRC) <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3591-3591	2.2	
20	Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 4445-52	2.2	136
19	Brush border myosin Ia inactivation in gastric but not endometrial tumors. <i>International Journal of Cancer</i> , <b>2013</b> , 132, 1790-9	7.5	20
18	A personalized preclinical model to evaluate the metastatic potential of patient-derived colon cancer initiating cells. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 6787-801	12.9	63
17	Molecular characterization of nonpancreatic neuroendocrine neoplasms (NENS): First description of mutations in the tumor suppressor gene (TSG) SMARCB1 in NENS of colorectal origin using next-generation sequencing (NGS) <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 4135-4135	2.2	
16	Etatenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. <i>Nature Medicine</i> , <b>2012</b> , 18, 892-901	50.5	281
15	Recomendaciones para la determinacifi de mutaciones de K-RAS en cficer de colon. <i>Revista Espanola De Patologia</i> , <b>2012</b> , 45, 76-85	1.2	3
14	Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials. <i>Molecular Cancer Therapeutics</i> , <b>2012</b> , 11, 2062-71	6.1	66

## LIST OF PUBLICATIONS

13	Brush border myosin Ia has tumor suppressor activity in the intestine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2012</b> , 109, 1530-5	11.5	50
12	Senescence, a new concept in pathologic response evaluation of rectal carcinomas (RC) after neoadjuvant treatment <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, e21021-e21021	2.2	
11	SPROUTY-2 and E-cadherin regulate reciprocally and dictate colon cancer cell tumourigenicity. <i>Oncogene</i> , <b>2010</b> , 29, 4800-13	9.2	54
10	Risk factors for positive findings in patients with high-grade T1 bladder cancer treated with transurethral resection of bladder tumour (TUR) and bacille Calmette-Gufin therapy and the decision for a repeat TUR. <i>BJU International</i> , <b>2010</b> , 105, 202-7	5.6	32
9	Aprataxin tumor levels predict response of colorectal cancer patients to irinotecan-based treatment. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 2375-82	12.9	31
8	The receptor tyrosine kinase EPHB4 has tumor suppressor activities in intestinal tumorigenesis. <i>Cancer Research</i> , <b>2009</b> , 69, 7430-8	10.1	52
7	Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. <i>Oncogene</i> , <b>2009</b> , 28, 803-14	9.2	316
6	p16 INK4a immunostaining identifies occult CIN lesions in HPV-positive women. <i>International Journal of Gynecological Pathology</i> , <b>2009</b> , 28, 90-7	3.2	44
5	Pre-operative chemoradiotherapy with UFT and Leucovorin in patients with advanced rectal cancer: a phase II study. <i>Radiotherapy and Oncology</i> , <b>2008</b> , 89, 263-9	5.3	12
4	Tumor trofobl¤tico epitelioide de presentaci¤ en la posmenopausia. <i>Progresos En Obstetricia Y Ginecologia</i> , <b>2007</b> , 50, 116-120	О	
3	p16 overexpression identifies HPV-positive vulvar squamous cell carcinomas. <i>American Journal of Surgical Pathology</i> , <b>2006</b> , 30, 1347-56	6.7	129
2	Poorly differentiated carcinomas of the thyroid with trabecular, insular, and solid patterns: a clinicopathologic study of 183 patients. <i>Cancer</i> , <b>2004</b> , 100, 950-7	6.4	168
1	Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin. 2002. 440, 461-75	5.1	238